236 related articles for article (PubMed ID: 20590856)
1. Animal models of inhibitors.
Reipert B; Arruda V; Lillicrap D
Haemophilia; 2010 Jul; 16 Suppl 5():47-53. PubMed ID: 20590856
[TBL] [Abstract][Full Text] [Related]
2. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
3. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
4. Urgent inhibitor issues: targets for expanded research.
Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():107-13. PubMed ID: 17123403
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory antibodies in hemophilia A.
Pratt KP
Curr Opin Hematol; 2012 Sep; 19(5):399-405. PubMed ID: 22814650
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor development in patients with hemophilia: an overview.
Leissinger CA
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
[No Abstract] [Full Text] [Related]
7. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
Rup B
Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
[TBL] [Abstract][Full Text] [Related]
8. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
10. Inhibitor development: patient-determined risk factors.
Astermark J
Haemophilia; 2010 May; 16(102):66-70. PubMed ID: 19298384
[TBL] [Abstract][Full Text] [Related]
11. Tolerance induction in hemophilia: innovation and accomplishments.
Sherman A; Biswas M; Herzog RW
Curr Opin Hematol; 2018 Sep; 25(5):365-372. PubMed ID: 29994897
[TBL] [Abstract][Full Text] [Related]
12. Prevention and prediction of inhibitor risk.
Astermark J
Haemophilia; 2012 Jul; 18 Suppl 4():38-42. PubMed ID: 22726081
[TBL] [Abstract][Full Text] [Related]
13. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
Kallas A; Kuuse S; Maimets T; Pooga M
Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
[No Abstract] [Full Text] [Related]
14. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
15. The management of hemophilia patients with inhibitors.
Nilsson IM
Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
[No Abstract] [Full Text] [Related]
16. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies.
Adair P; Su Y; Scott DW
Discov Med; 2013 May; 15(84):275-82. PubMed ID: 23725600
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of factor VIII in hemophilia.
Lacroix-Desmazes S; Dimitrov JD; Repesse Y
N Engl J Med; 2009 Jul; 361(3):308; author reply 310. PubMed ID: 19605840
[No Abstract] [Full Text] [Related]
18. Inhibitors in young boys with haemophilia.
Lusher JM
Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
[TBL] [Abstract][Full Text] [Related]
19. New predictive approaches for ITI treatment.
Minno GD; Santagostino E; Pratt K; Königs C
Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
[TBL] [Abstract][Full Text] [Related]
20. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
Gouw SC; van den Berg HM
Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
